

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Use of [4,6-Di-¹⁴C]-5'-DMT-thymidine Phosphoramidite Reagent for the Radiolabeling of Synthetic Oligonucleotides

Andrei Guzaev^a; Brunel Boyode^b; Guity Balow^a; Muthiah Manoharan^a

^a Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA ^b Moravsek Biochemicals, Inc., Brea, CA

To cite this Article Guzaev, Andrei , Boyode, Brunel , Balow, Guity and Manoharan, Muthiah(1999) 'Use of [4,6-Di-¹⁴C]-5'-DMT-thymidine Phosphoramidite Reagent for the Radiolabeling of Synthetic Oligonucleotides', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 6, 1389 – 1390

To link to this Article: DOI: 10.1080/07328319908044726

URL: <http://dx.doi.org/10.1080/07328319908044726>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.


USE OF [4,6-DI- ^{14}C]-5'-DMT-THYMIDINE PHOSPHoramidite REAGENT FOR THE RADIOLABELING OF SYNTHETIC OLIGONUCLEOTIDES

Andrei Guzaev,* Brunel Boyode,[#] Guity Balow, and Muthiah Manoharan
Department of Medicinal Chemistry, Isis Pharmaceuticals, 2280 Faraday Ave., Carlsbad,
CA 92008;

[#]Moravek Biochemicals, Inc., 577 Mercury Ln., Brea, CA 92821

ABSTRACT: A novel synthesis of 5'-radiolabeled oligonucleotides is described. The labeling is carried out by the phosphoramidite method with the aid of building block **1**. The feasibility of the method is demonstrated by preparation of 5'-radiolabeled 3'-phosphorylated dodecathymidylate phosphorothioate.

Labeling with radioactive isotopes provides an efficient tool for studying pharmacological properties of antisense oligonucleotides. As with other classes of drug compounds, this novel class of therapeutics requires high sensitivity radiodetection for evaluation of distribution of antisense agents in tissues and assessment of their metabolic fate. Several methods to introduce ^{35}S , ^3H , or ^{14}C into synthetic oligonucleotides have been reported. Among these labels, ^{14}C offers the highest specific activity and the longest half-life. Considering catabolism of nucleic acids, labeling with ^{14}C at the C-2 position of thymidine results in formation of $^{14}\text{CO}_2$ which is cumbersome to trap and analyze. On the other hand, labeling at either the C-4 or C-6 position leads to β -aminoisobutyric acid as the metabolite which is much more convenient to analyze.



In this communication, the incorporation of radioisotope is achieved with the aid of phosphoramidite reagent **1** that is derived from [4,6-di- ^{14}C]thymidine and thus possesses high specific activity.² Phosphoramidite **1** features the *S*-pivaloyl 2-mercaptoethyl

(SPME) group which has recently been reported as an enzyme-labile phosphate protecting group.¹ As the first step in our study of bioreversible protection of the internucleosidic (thio)phosphate moiety, we applied **1** to the preparation of phosphorothioate oligonucleotides.

To synthesize phosphoramidite reagent **1**, *bis*-(diisopropylamino)chlorophosphine, was reacted with *S*-pivaloyl-2-mercaptoethanol to give corresponding bisamidite. (125.3 ppm; 70-75% yield). In the next step, [4,6-di-¹⁴C]-DMT-T was treated with crude bisamidite in the presence of 1*H*-tetrazole followed by standard work-up.

Half-life of non-radioactive **1** (**1a**) in 80% aq MeCN was found to be 58 h, which permits safe isolation of **1** in aqueous media. Accordingly, crude product was purified by RP HPLC to give **1** in 78.8% yield.

In optimal condition, coupling procedure with **1** consisted of 3 main steps. First, a solid support bound oligonucleotide (10 μmol) was dried by treatment with a mixture of **1a** (10 μmol) and 1*H*-tetrazole for 1 min. This step was designed to result in a very low coupling yield (5 to 10%) due to the low concentration of the phosphoramidite. However, it efficiently consumed any traces of water that were not removed by washing with acetonitrile and extended drying. Next, solution of **1** (20 μmol) was delivered to the solid support followed by 1*H*-tetrazole, and the reaction mixture was kept for 20 min. Washing the support and performing the sulfurization reaction completed the step. As determined by DMT assay, coupling efficiency of **1** was 83% (41% yield with respect to **1**). Finally, the solid support was coupled with **1a** (50 μmol) and excess 1*H*-tetrazole in order to obtain uniform full-length support-bound oligonucleotide. After sulfurization, the product was treated with concentrated ammonia. Crude radiolabeled T*p(Tp)₁₁ was isolated by RP HPLC in 60% yield. The labeled product was analyzed by MALDI-TOF mass spectrometry and anion exchange HPLC to confirm the presence of homogeneous oligonucleotide free from any radioactive impurities.

REFERENCES

1. Tosquellas, G.; Alvarez, K.; Dell'Aquila, K.; Morvan, F.; Vasseur, J.-J.; Imbach, J.-L.; Rayner, B. (1998) *Nucleic Acids Res.*, **26**, 2069-2074, and references cited therein.
2. Guzaev, A.; Boyde, B.; Balow, G.; Tivel, K.L.; and Manoharan, M. (1998) *Bioorg. Med. Chem. Lett.*, **8**, 1123-1126.